FY2030 EPS Estimates for Rezolute Cut by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Investment analysts at HC Wainwright lowered their FY2030 EPS estimates for shares of Rezolute in a research note issued on Friday, November 7th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.49 per share for the year, down from their prior forecast of $0.61. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share.

Other equities analysts have also recently issued research reports about the company. BTIG Research reaffirmed a “buy” rating and issued a $17.00 price target on shares of Rezolute in a report on Thursday, September 18th. Wedbush restated an “outperform” rating and issued a $12.00 target price on shares of Rezolute in a research note on Thursday, September 18th. JMP Securities set a $17.00 price target on shares of Rezolute in a research note on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Wednesday, October 8th. Finally, Guggenheim restated a “buy” rating and issued a $15.00 price objective on shares of Rezolute in a research note on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Rezolute Stock Performance

NASDAQ RZLT opened at $9.95 on Monday. Rezolute has a twelve month low of $2.21 and a twelve month high of $11.46. The stock has a market cap of $903.76 million, a PE ratio of -10.70 and a beta of 0.07. The firm has a 50-day simple moving average of $8.72 and a 200 day simple moving average of $6.29.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.09.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund boosted its holdings in shares of Rezolute by 5.6% in the 3rd quarter. New York State Common Retirement Fund now owns 24,600 shares of the company’s stock worth $231,000 after acquiring an additional 1,300 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Rezolute by 5.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock valued at $312,000 after purchasing an additional 1,567 shares in the last quarter. Pale Fire Capital SE raised its position in Rezolute by 4.2% in the 2nd quarter. Pale Fire Capital SE now owns 49,122 shares of the company’s stock valued at $219,000 after purchasing an additional 2,000 shares during the last quarter. Huntleigh Advisors Inc. raised its position in Rezolute by 16.7% in the 3rd quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock valued at $164,000 after purchasing an additional 2,500 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Rezolute by 5.2% in the first quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock worth $197,000 after purchasing an additional 3,334 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.